Molnupiravir for the treatment of COVID-19
- PMID: 35851869
- DOI: 10.1358/dot.2022.58.7.3419558
Molnupiravir for the treatment of COVID-19
Abstract
Molnupiravir (MK-4482, EIDD-2801) is a promising broad-spectrum experimental antiviral developed by Merck & Co. It is a nucleoside analogue prodrug that undergoes rapid conversion into nucleoside triphosphate (NTP) by intracellular metabolic processes. NTP inhibits viral polymerase by acting as an alternative substrate. Molnupiravir was initially developed to treat influenza and Venezuelan equine encephalitis virus (VEEV) infection as it exerts its antiviral activity by inhibiting RNA-dependent RNA polymerase (RdRp). Currently, it is being developed for the treatment of SARS-CoV-2 infection. Molnupiravir has demonstrated potent in vitro antiviral activity against positive-sense RNA viruses including influenza viruses, SARS-CoV, SARS-CoV-2 and MERS-CoV with low cytotoxicity and a high resistance barrier. Molnupiravir has been evaluated in phase I, II and III trials where it has demonstrated good efficacy, dose-dependent pharmacokinetics and a sound safety profile. In an interim analysis of a phase III study, treatment with molnupiravir reduced the risk of hospitalization or death by 50% in patients with COVID-19; in the final analysis, the reduction was 30%. On the basis of positive results in clinical trials, molnupiravir has been authorized for emergency use by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and the U.S. Food and Drug Administration (FDA) in adults with mild to moderate COVID-19.
Keywords: Anti-SARS-CoV-2 agents; Antiviral drugs; COVID-19; Molnupiravir; Nucleoside analogues; RNA-dependent RNA polymerase (RdRp) inhibitors; Viral replication inhibitors.
Copyright 2022 Clarivate.
Similar articles
-
Molnupiravir and Its Antiviral Activity Against COVID-19.Front Immunol. 2022 Apr 4;13:855496. doi: 10.3389/fimmu.2022.855496. eCollection 2022. Front Immunol. 2022. PMID: 35444647 Free PMC article. Review.
-
RdRp inhibitors and COVID-19: Is molnupiravir a good option?Biomed Pharmacother. 2022 Feb;146:112517. doi: 10.1016/j.biopha.2021.112517. Epub 2021 Dec 9. Biomed Pharmacother. 2022. PMID: 34902743 Free PMC article. Review.
-
Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.J Med Virol. 2022 Jul;94(7):3006-3016. doi: 10.1002/jmv.27730. Epub 2022 Apr 2. J Med Virol. 2022. PMID: 35315098 Free PMC article. Review.
-
Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.Viruses. 2022 Jun 20;14(6):1345. doi: 10.3390/v14061345. Viruses. 2022. PMID: 35746815 Free PMC article. Review.
-
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.Molecules. 2021 Sep 24;26(19):5795. doi: 10.3390/molecules26195795. Molecules. 2021. PMID: 34641339 Free PMC article. Review.
Cited by
-
Editorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is Declared.Med Sci Monit. 2023 Nov 1;29:e942960. doi: 10.12659/MSM.942960. Med Sci Monit. 2023. PMID: 37908161 Free PMC article.
-
Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients.Viruses. 2022 Oct 9;14(10):2224. doi: 10.3390/v14102224. Viruses. 2022. PMID: 36298779 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous